The Diabetes Genetics Initiative is a collaboration of the Broad Institute of MIT and Harvard, Lund University, and Novartis Institutes for BioMedical Research
The Diabetes Genetics Initiative combines the resources and expertise of the Novartis Institutes for BioMedical Research, the Broad Institute of MIT and Harvard, and Lund University to identify the genetic determinants of type 2 diabetes. This unique collaboration aims to collect and analyze samples from type 2 diabetic patients from nations across the globe, performing whole genome scans to provide a comprehensive view of the DNA sequence variants associated with the disease. This partnership has been forged with the explicit goal of making this vast amount of crucial data available to researchers globally and free of cost, which should lead to a greater understanding of disease biology and speed the development of more effective therapies.
Although the astounding generosity of Eli and Edythe L. Broad and several other venture philanthropists empowers our scientists to tackle many of the most important problems at the cutting edge of genomic medicine, there are many other critical challenges that they cannot yet pursue because of limited resources. We need additional visionary partners to join the Broads and the Broad Institute in transforming medicine with the power of genomics.
Resource Type: Resource
Version: Latest Version
Additional Resource Types
Created 5 years ago by Anonymous